Antibodies in Patients With Rare Disorder may Prevent Type 1 Diabetes and Psoriasis

The antibodies were derived from people with a rare autoimmune disorder, called autoimmune polyendocrine syndrome type 1 (APECED).

People with a rare autoimmune disorder produce antibodies that may have therapeutic potential for Type 1 diabetes and psoriasis, according to a study conducted on mice.

An international team, led by researchers from King's College London, analyzed samples taken from 81 people with a rare autoimmune disorder called autoimmune polyendocrine syndrome type 1 (APECED).

Autoimmune Disease Lupus Linked With 10 New Genes
One gene in particular, known as GTF2I, showed a high likelihood of being involved in the development of lupus.

‘The autoantibodies commonly produced by people with autoimmune polyendocrine syndrome type 1 (APECED) was found to inhibit the development of psoriatic pathology.’

To discover if APECED patients' autoantibodies could have therapeutic potential, the team tested them in a mouse model of psoriasis.

They found that injecting the mice with autoantibodies from the APECED patients could inhibit the development of psoriatic pathology.

The team also found that increased T cell auto-reactivity in patients with APECED was linked with increased B-cell auto-reactivity. B cells are a type of immune cell that produces antibodies.

Phase I Clinical Studies For Antibody to Treat Autoimmune Disease Completed by Glenmark
Swiss subsidiary of Glenmark Pharmaceuticals announced that GBR 830, a novel monoclonal antibody has completed clinical phase 1 dosing in Netherlands.

"This is very significant because antibodies make up one of the largest sectors of the pharmaceutical market, and one of the great quests in the pharmaceutical industry is to be able to routinely generate antibodies against human proteins implicated in diseases," said Adrian Hayday from King's College London.

"The findings suggest a route to drug recovery in which, naturally arising highly-efficacious autoantibodies can be isolated from patients whose clinical information guides us as to the diseases most likely to benefit from those antibodies," he added in a paper published in the journal Cell.

Immune Cells That Promote Growth of Beta Cells in Type 1 Diabetes Identified By Joslin Researchers
Immune cells that promote growth of beta cells in type 1 diabetes were identified by Joslin researchers.

Source-IANS

New Drug 'Ixekizumab' Clears Moderate to Severe Psoriasis in Clinical Trials
About 80% of patients with moderate to severe psoriasis saw their disease completely or almost completely cleared with a new drug called ixekizumab.